A practical reference on LC-MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-12. Anything still debated is marked as such rather than presented as settled.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
In May 2002, The Bill & Melinda Gates Foundation purchased stock in Merck. From 2002 through 2005, the Australian affiliate of Merck paid publishing house Elsevier an undisclosed amount to produce eight issues of a medical journal, the Australasian Journal of Bone and Joint Medicine. Although it gave the appearance of being an independent peer-reviewed journal, without any indication that Merck had paid for it, the journal actually reprinted articles that originally appeared in other publications and that were favorable to Merck. The misleading publication came to light in 2009 during a personal injury lawsuit filed over Vioxx; 9 of 29 articles in the journal's second issue referred positively to Vioxx. The CEO of Elsevier's Health Sciences Division, Michael Hansen, admitted that the practice was "unacceptable". Elsevier initially said that it compiled reprinted articles and it did not consider such compilation a journal. It was later forced to retreat and apologize. In 2005, Gilmartin retired as CEO following Merck's voluntary worldwide withdrawal of Vioxx. Gilmartin's tenure was criticized as abandoning Vagelos' commitment to corporate social responsibility. Former president of manufacturing Richard Clark was named CEO and company president. In November 2009, Merck & Co. completed a merger with Schering-Plough in a US$41 billion deal. Although Merck & Co. was in reality acquiring Schering-Plough, the purchase was declared a "reverse merger", in which "Old" Merck & Co.
=== Analogues === Although several related compounds are disclosed in the original patent, no activity data are provided and it was unclear whether these share tianeptine's unique pharmacological effects. More recent structure-activity relationship studies have since been conducted, providing some further insight on μ-opioid, δ-opioid, and pharmacokinetic activity. Derivatives where the aromatic chlorine substituent is replaced by bromine, iodine or methylthio, and/or the heptanoic acid tail is varied in length or replaced with other groups such as 3-methoxypropyl, show similar or increased opioid receptor activity relative to tianeptine, with up to 13x higher potency than tianeptine itself. Amineptine, the most closely related drug to have been widely studied, is a dopamine reuptake inhibitor with no significant effect on serotonin levels, nor opioid agonist activity. Tianeptinaline and tianeptinostat, analogues of tianeptine, are potent histone deacetylase (HDAC) inhibitors.
=== Food products === In 1909, Ajinomoto Co. Inc. released its umami seasoning AJI-NO-MOTO, made from molasses and tapioca starch derived from sugarcane. In Asia and Latin America, the product was primarily sold to consumers, while in North America and Europe it was mostly sold to processed food manufacturers. In 1970, Ajinomoto launched the bonito flavored seasoning HON-DASHI in Japan, and later adapted the product to other markets with local flavors. In 1978 Ajinomoto released Cook Do, a series of Chinese cuisine seasoning products, and later added other cuisine seasoning flavors to the Cook Do product line. The company entered the frozen food business in 1972, and currently sells a variety of frozen food products, including dumplings, noodles, and cooked rice. In 1982, Ajinomoto Co., Inc. entered the sweetener business by producing aspartame. In 1984 it released a low-calorie consumer sweetener PAL SWEET. By 2021, Ajinomoto was ranked 6th overall and 1st in Asia on FoodTalks' Top 50 Global Sweetener Companies list. Ajinomoto Co., Inc. is the world's largest manufacturer of aspartame, sold under the trade name Aminosweet. Ajinomoto also sells soup, mayonnaise, porridge, pasta sauce, and instant noodles under the "VONO" brand name. Through Ajinomoto AGF Corporation, Ajinomoto sells instant coffee, regular coffee, bottled coffee, stick coffee, and canned coffee, and is the top coffee brand in Thailand with a 70% market share. Ajinomoto's Yum Yum brand of instant noodles in 2019 held a 20–21% share of Thailand's 17 billion baht instant noodle market.
The former republics were transformed into the British colonies of the Transvaal and Orange River, and in 1910 were merged with the Natal and Cape Colonies to form the Union of South Africa, a self-governing colony within the British Empire. British expeditionary efforts were aided significantly by colonial forces from the Cape Colony, the Natal, Rhodesia, and many volunteers from the British Empire. Native African recruits contributed increasingly to the British effort. International public opinion was sympathetic to the Boers and hostile to the British. Even within the UK, there existed significant opposition to the war. As a result, the Boer cause attracted volunteers from neutral countries, including the German Empire, the United States, Russia and parts of the British Empire, such as Australia and Ireland. Some consider the war the beginning of questioning the British Empire's global dominance, due to the war's surprising duration and unforeseen losses suffered by the British. A trial for British war crimes, including the killings of civilians and prisoners of war, was opened in January 1902. The war had a lasting effect on the region and on British domestic politics.
Blood Coagulation factor VII with the name of AryoSeven Altebrel with the generic name of Etanercept and original trade name of Enbrel Zytux with the generic name of Rituximab and original trade name of Rituxan َAryoTrust with the generic name of trastuzumab and original name of Herceptin Stivant with the generic name of bevacizumab and original trade name of Avestin AryoSeven is now approved by Iranian food and drug organisation and from August 2012 is in the market.
Sources: en.wikipedia.org
==== Endogenous DMT ==== N,N-Dimethyltryptamine (DMT), a psychedelic compound identified endogenously in mammals, is biosynthesized by aromatic L-amino acid decarboxylase (AADC) and indolethylamine-N-methyltransferase (INMT). Studies have investigated brain expression of INMT transcript in rats and humans, coexpression of INMT and AADC mRNA in rat brain and periphery, and brain concentrations of DMT in rats. INMT transcripts were identified in the cerebral cortex, pineal gland, and choroid plexus of both rats and humans via in situ hybridization. Notably, INMT mRNA was colocalized with AADC transcript in rat brain tissues, in contrast to rat peripheral tissues where there existed little overlapping expression of INMT with AADC transcripts. Additionally, extracellular concentrations of DMT in the cerebral cortex of normal behaving rats, with or without the pineal gland, were similar to those of canonical monoamine neurotransmitters including serotonin. A significant increase of DMT levels in the rat visual cortex was observed following induction of experimental cardiac arrest, a finding independent of an intact pineal gland. These results show for the first time that the rat brain is capable of synthesizing and releasing DMT at concentrations comparable to known monoamine neurotransmitters and raise the possibility that this phenomenon may occur similarly in human brains. The first claimed detection of endogenous DMT in mammals was published in June 1965: German researchers F. Franzen and H.
TsrM in thiostrepton biosynthesis PoyD and PoyC in polytheonamide biosynthesis TbtI in thiomuracin biosynthesis NosN in nosiheptide biosynthesis EpeE (previously called YydG) in epipeptide biosynthesis MoaA in molybdopterin biosynthesis PqqE in pyrroloquinoline quinone biosynthesis TunB in tunicamycin biosynthesis OxsB in oxetanocin biosynthesis BchE in anaerobic bacteriochlorophyll biosynthesis F0 synthases in F420 cofactor biosynthesis MqnE and MqnC in menaquinone biosynthesis QhpD in post-translational processing of quinohemoprotein amine dehydrogenase RumMC2 in ruminococcin C biosynthesis
Human Vapor (Japanese: ガス人間; Korean: 가스인간) is a 2026 science fiction crime thriller television series based on the 1960 tokusatsu film The Human Vapor by Ishirō Honda and Takeshi Kimura. A Japanese–South Korean co-production written by Yeon Sang-ho and Ryu Yong-jae and directed by Shinzo Katayama, the series stars Shun Oguri, Yu Aoi, Suzu Hirose, Kento Hayashi, Uta, and Yutaka Takenouchi. It is produced by Toho Studios and Wow Point, marking the first collaboration between Netflix and Toho, and was released on Netflix on July 2, 2026.
Each PLA probes comes with a unique short DNA strand attached to it and bind either to species specific primary antibodies or consist of directly DNA-labeled primary antibodies. When the PLA probes are in close proximity, the DNA strands can interact through a subsequent addition of two other circle-forming DNA oligonucleotides. After joining of the two added oligonucleotides by enzymatic ligation, they are amplified via rolling circle amplification using a polymerase. After the amplification reaction, several-hundredfold replication of the DNA circle has occurred and flurophore or enzyme labeled complementary oligonucleotide probes highlight the product. The resulting high concentration of fluorescence or cromogenic signal in each single-molecule amplification product is easily visible as a distinct bright spot when viewed with either in a fluorescence microscope or a standard brightfield microscope.
==== Dispersive liquid–liquid microextraction (dLLME) ==== Dispersive liquid-liquid microextraction is process used to extract organic compounds from water samples, typically at a smaller scale than LLE using a separatory funnel. In this process, an extraction solvent immiscible with water is mixed with a dispersive solvent. The mixture is injected into the aqueous sample to be extracted, forming a dispersion of small organic droplets in the aqueous sample. The resulting suspension is then centrifuged to coalesce the organic droplets and separate the organic and aqueous layers. The organic phase can then be removed using a microsyringe or other tool. Chlorinated solvents are commonly used as the extractive solvent as their higher density makes them settle to the bottom of centrifuge tubes. Acetone is a common dispersive solvent. dLLME is favored for its relatively low use of organic solvent for a batch extraction process which can reduce costs. The lower solvent usage means dLLME can be considered a "green chemistry" process though common use of chlorinated solvents as the organic phase is typically considered antithetical to green chemistry principles. This process is useful in extraction organic compounds such as organochloride and organophosphorus pesticides, as well as substituted benzene compounds from water samples.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
SR9009 is a synthetic compound investigated as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is used in preclinical research on circadian rhythm and metabolism. It is not an approved drug.